Tenderwize
Back to tender search

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 191 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Certolizumab pegol , ATC L04AB05

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount agreements for Certolizumab pegol (ATC L04AB05) under the open-house model.
  • Contracts have uniform terms and conditions, no individual negotiations.
Show full summary

Non-exclusive discount agreement (open-house model) for the active substance Certolizumab pegol (ATC L04AB05), offered by AOK Rheinland-Pfalz/Saarland. All interested pharmaceutical companies meeting eligibility may join at uniform terms. Contracts run max 24 months (earliest start 01.05.2025, ending 30.04.2027). The buyer may replace with exclusive contracts during the term. First submission deadline: 31.03.2025; subsequent monthly deadlines. Notice is a voluntary transparency publication, not a formal EU procurement.

Risks

Non-exclusive contracts mean market share is not guaranteed; multiple competitors may participate, diluting potential v...

Buyer may replace open-house contracts with exclusive agreements at any time, terminating these contracts early.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Evidence of marketability via Lauer-Taxe listing or AMIce database extract required.

Eligibility

  • Only pharmaceutical products authorized and marketable in Germany are eligible.

Administrative

  • Submission of signed contract documents and required evidence by the specified deadlines.

Award Criteria

Lot 1

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Buyer

Lots (1)

LOT-0001

Open House Discount Agreements for Certolizumab pegol, ATC L04AB05

Non-exclusive discount contracts for the supply of pharmaceutical products containing the active substance Certolizumab pegol (ATC L04AB05) to the AOK Rheinland-Pfalz/Saarland. All qualified pharmaceutical companies can join on standard terms. Duration: up to 24 months from 01.05.2025 to 30.04.2027. Rolling entry possible monthly. Uniform conditions, no negotiations. Subject to early termination if buyer awards exclusive contracts.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Award Criteria

No award criteria are applied as the open-house model accepts all qualifying participants. Eligibility is the sole condition.

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
12 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
164685-2025

Documents (1)

Similar tenders